INHBE (human, recombinant)

Inhibin beta E chain (INHBE) is a member of the TGF-beta superfamily. INHBE encodes a 350-amino acid pre-protein, which is proteolytically cleaved at Thr237 to release the mature INHBE peptide, and is a secreted protein mainly expressed in the liver. It exists as a homodimer, also known as activin E, or forms heterodimers with other inhibin beta chains such as INHBC. INHBE is a hepatokine that is involved in hepatocyte viability, thermogenesis, and insulin sensitivity and binds to follistatin (Cay-31839). Overexpression of INHBE induces apoptosis in hepatocytes and INHBE-containing conditioned medium induces expression of genes involved in adipocyte differentiation, which can be blocked by the activin receptor-like kinase (ALK) inhibitor SB-431542 (Cay-13031). Hepatic expression of human INHBE decreases plasma glucose levels and increases body temperature in mice. Loss-of-function mutations in INHBE are associated with favorable body fat distribution and a decreased risk of developing type 2 diabetes. Increased tumor levels of INHBE positively correlate with increasing tumor grade and negatively correlate with poor overall survival in patients with clear-cell renal cell carcinoma (ccRCC). Cayman's INHBE (human, recombinant) protein is a disulfide-linked homodimer. The reduced monomer, composed of INHBE (amino acids 237-350) fused to human IgG1 Fc at its N-terminus, consists of 374 amino acids and has a calculated molecular weight of 40.9 kDa.Synonyms: Activin beta-E Chain, Inhibin beta-E Chain, Inhibin Subunit beta E. Purity: >90% as determined by SDS-PAGE. Endotoxin Testing: <1.0 EU/µg determined by the LAL endotoxin assay. Source: Recombinant N-terminal human IgG1 Fc-tagged INHBE expressed in HEK293 cells. Amino Acids: 237-350. MW: 40.9 kDa. Formulation: (Request formulation change), Lyophilized from sterile PBS, pH 7.4, with 5% trehalose, 5% mannitol, and 0.01% Tween 80. UniProt Accession #: P58166.